Literature DB >> 22920370

A rare case report of a primary large-cell neuroendocrine carcinoma of the breast with coexisting Paget disease.

Elizabeth Psoma1, Olga Nikolaidou, Thomai Stavrogianni, Areti Mavromati, Konstantinos Lytras, Persefoni Xirou, Melanie Koumbanaki, Dimitra Panagiotopoulou.   

Abstract

Neuroendocrine carcinomas are malignancies deriving from neuroendocrine cells existing in various sites of the body, most commonly in the lungs and gastrointestinal tract. Primary neuroendocrine carcinomas of the breast are extremely rare, and their diagnosis is confirmed by positive neuroendocrine markers. We describe a case of a 46-year-old woman with a palpable mass in her left breast for the previous 3 months. The tumor was resected and a primary large-cell neuroendocrine tumor of the breast was confirmed by histopathologic examination. Paget disease of the nipple was noted as well.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22920370     DOI: 10.1016/j.clinimag.2011.10.004

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  3 in total

1.  A high-quality model for predicting the prognosis of breast neuroendocrine carcinoma to help clinicians decide on appropriate treatment methods: A population-based analysis.

Authors:  Yu-Qiu Chen; Xiao-Fan Xu; Jia-Wei Xu; Tian-Yu Di; Xu-Lin Wang; Li-Qun Huo; Lu Wang; Jun Gu; Guo-Hua Zhou
Journal:  Transl Oncol       Date:  2022-06-11       Impact factor: 4.803

2.  [Primary large cell neuroendocrine carcinoma of the breast: a rare tumor in humans].

Authors:  Fatima Safini; Zineb Bouchbika; Zineb Bennani; Sara Belkheiri; Hicham El Attar; Nadia Benchakroun; Hassan Jouhadi; Nezha Tawfiq; Souha Sahraoui; Abdellatif Benider
Journal:  Pan Afr Med J       Date:  2016-11-29

Review 3.  Neuroendocrine breast carcinoma: a rare but challenging entity.

Authors:  Elena Trevisi; Anna La Salvia; Lorenzo Daniele; Maria Pia Brizzi; Giovanni De Rosa; Giorgio V Scagliotti; Massimo Di Maio
Journal:  Med Oncol       Date:  2020-07-25       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.